The FDA has approved a new vaccine called Penmenvy to protect against meningococcal disease. It is made by GSK and is for people aged 10 to 25.
Penmenvy protects against five types of bacteria that can cause serious infections. It combines two existing vaccines, Bexsero and Menveo, into one shot.
The vaccine is given as an injection into the muscle. It was tested in over 4,800 people in phase 3 trials.
Results showed that Penmenvy is safe and works well to trigger an immune response. Its safety profile is similar to other meningococcal vaccines from GSK.
Common side effects include pain at the injection site, fatigue, headache, muscle pain, and nausea.
Experts say this vaccine makes it easier for adolescents to get full protection against meningococcal disease.
Source: www.pulmonologyadvisor.com/news/fda-approves-more-broadly-protective-meningococcal-vaccine/
